ctDNA improves prognostic prediction for patients with relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone.

MLA

Kogure, Yasunori, et al. “CtDNA Improves Prognostic Prediction for Patients with Relapsed/Refractory MM Receiving Ixazomib, Lenalidomide, and Dexamethasone.” Blood, vol. 143, no. 23, June 2024, pp. 2401–13. EBSCOhost, https://doi.org/10.1182/blood.2023022540.

APA

Kogure, Y., Handa, H., Ito, Y., Ri, M., Horigome, Y., Iino, M., Harazaki, Y., Kobayashi, T., Abe, M., Ishida, T., Ito, S., Iwasaki, H., Kuroda, J., Shibayama, H., Sunami, K., Takamatsu, H., Tamura, H., Hayashi, T., Akagi, K., … Kataoka, K. (2024). ctDNA improves prognostic prediction for patients with relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone. Blood, 143(23), 2401–2413. https://doi.org/10.1182/blood.2023022540

Chicago

Kogure, Yasunori, Hiroshi Handa, Yuta Ito, Masaki Ri, Yuichi Horigome, Masaki Iino, Yoriko Harazaki, et al. 2024. “CtDNA Improves Prognostic Prediction for Patients with Relapsed/Refractory MM Receiving Ixazomib, Lenalidomide, and Dexamethasone.” Blood 143 (23): 2401–13. doi:10.1182/blood.2023022540.